[1]吴郁,姚颖,李文静,等.DNA损伤修复相关因子在宫颈癌组织中表达的研究[J].中国微创外科杂志,2018,18(3):256-259.
　Wu Yu,Yao Ying,Li Wenjing,et al.The Study on Expression of DNA Damage Repair Factors in Cervical Tissues From Patients With Cervical Cancer[J].Chinese Journal of Minimally Invasive Surgery,2018,18(3):256-259.
点击复制

DNA损伤修复相关因子在宫颈癌组织中表达的研究()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
18
期数:
2018年3期
页码:
256-259
栏目:
实验研究
出版日期:
2018-05-01

文章信息/Info

Title:
The Study on Expression of DNA Damage Repair Factors in Cervical Tissues From Patients With Cervical Cancer
作者:
吴郁; 姚颖; 李文静; 金一枚; 杨沫; 郭红燕*
北京大学第三医院妇产科，北京100191
Author(s):
Wu Yu;  Yao Ying;  Li Wenjing;  et al.
Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China
关键词:
DNA损伤标记物; 宫颈癌; 磷酸化H2AX; 磷酸化毛细血管扩张性共济失调突变因子
Keywords:
DNA damage marker; Cervical cancer; γH2AX; Phosphoataxia telangiectasia mutation
文献标志码:
A
摘要:
目的探讨DNA损伤修复相关因子组蛋白H2AX和毛细血管扩张性共济失调突变因子（ataxia telangiectasia mutation，ATM）在宫颈癌组织中的表达水平及诊断意义。方法选取2016年1月~2017年7月我科宫颈癌30例（宫颈癌组），同时选取非宫颈癌18例为对照组，对宫颈癌组和对照组宫颈组织进行HE染色和免疫组化染色，在mRNA水平检测H2AX和ATM的表达情况，以磷酸化抗体检测磷酸化H2AX（γH2AX）与磷酸化ATM（phosphoataxia telangiectasia mutation，pATM）水平。结果荧光定量PCR分析宫颈癌组ATM mRNA为2.8546±0.8881，明显高于对照组1.0018±0.4980（t=9256，P=0.000）；宫颈癌组H2AX mRNA为2.4312±0.8224，显著高于对照组0.7896±0.4791（t=8738，P=0.000）。γH2AX和pATM主要在细胞核中表达, γH2AX阳性率80.0%（24/30），显著高于对照组11.1%（2/18）（Z=-3.381，P=0000）；宫颈癌组pATM阳性率83.3%（25/30），显著高于对照组16.7%（3/18）（Z=-4.031，P=0.000）。结论γH2AX和pATM在宫颈癌中高表达，作为DNA损伤修复因子对宫颈癌的早期诊断有一定的临床意义。
Abstract:
ObjectiveTo investigate the expression, activation, and significance on diagnosis of DNA damage repair factors H2AX and ataxia telangiectasia mutation (ATM) in cervical tissues from patients with cervical cancer. MethodsThirty patients with cervical cancer from January 2016 to July 2017 in our hospital were enrolled as study subjects (cervical cancer group). At the same time, 18 patients with noncervical cancer were selected as the control group. Both groups were given HE staining as well as immunohistochemical staining of the cervical tissues. The expressions of H2AX and ATM were detected at the mRNA level, and phosphorylated H2AX (γH2AX) and phosphoataxia telangiectasia mutation (pATM) were detected with phosphorylated antibody assays.ResultsThe realtime quantitative PCR showed the mRNA expression of ATM of (2.8546±0.8881) in the cervical cancer group, which was significantly higher than that in the control group (1.0018±0.4980, t=9.256, P=0.000). The mRNA expression of H2AX was (2.4312±0.8224) in the cervical cancer group, which was significantly higher than that in the control group (0.7896±0.4791, t=8.738, P=0.000). The γH2AX and pATM were mainly expressed in the nucleus of cancer cells. The positive rate of γH2AX in the cervical cancer group was 80.0% (24/30), significantly higher than that in the control group ［11.1% (2/18), Z=-3.381, P=0000］. And the positive rate of pATM in the cervical cancer group was 83.3% (25/30), significantly higher than that in the control group ［16.7% (3/18), Z=-4.031, P=0.000］.ConclusionsThe γH2AX and pATM are highly expressed in cervical tissues from patients with cervical cancer. As the DNA damage repair factors, the γH2AX and pATM might have certain clinical significance in early diagnosis of cervical cancer.

参考文献/References:

[1]应倩,夏庆民,郑荣寿,等.中国2009年宫颈癌发病与死亡分析.中国肿瘤，2013，22(8)：612-616.
[2]张昕蕾,张军,蔡有芹,等.腹腔镜手术治疗108例宫颈癌的临床分析.中国微创外科杂志,2016,16(11):980-982.
[3]Larsen DH,Stucki M.Nucleolar responses to DNA doublestrand breaks.Nucleic Acids Res,2016,44(2):538-544.
[4]Vici P, Buglioni S, Sergi D, et al.DNA damage and repair biomarkers in cervical cancer patients treated with neoadjuvant chemotherapy: an exploratory analysis.PloS One,2016,11(3):e0149872.
[5]Cuppens T, Annibali D, Coosemans A, et al. Potential targets’ analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine leiomyosarcomasan ENITEC Group initiative. Clin Cancer Res,2017,23(5):1274-1285.
[6]李英伟,刘海枝.宫颈癌高危因素及检测的研究进展.中外医疗,2010,29(5)：98-99.
[7]郑晓霞,李琼珍,李玲,等.宫颈癌预后状况及其影响因素分析.实用癌症杂志，2014，29(3)：314-316.
[8]Wright TC Jr, Massad LS, Dunton CJ, et al.2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol,2007,197(4):340-345.
[9]黄晓园,李琼珍,马丁,等. Chkl /2和Pl kl 蛋白在宫颈良恶性病变组织中的表达及其意义.中国癌症杂志,2007,17(6):429-432.
[10]Jin Y,Xu X,Li M,et al.Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer. Oncotarget,2016,7(31):49710-49721.
[11]Turinetto V, Giachino C. Multiple facets of histone variant H2AX: a DNA doublestrandbreak marker with several biological functions. Nucleic Acids Res,2015,43(5):2489-2498.
[12]Larsen DH, Stucki M. Nucleolar responses to DNA doublestrand breaks. Nucleic Acids Res,2016,44(2):538-544.
[13]Roossink F, Wieringa HW, Noordhuis MG, et al.The role of ATM and 53BP1 as predictive markers in cervical cancer.Int J Cancer,2012,131(9):2056-2066.
[14]Zhao J, Wang Q, Li J, et al.Comparative study of phosphorylated histone H2AX expressions in the cervical cancer patients of pre and postneoadjuvant chemotherapy.Eur J Gynaecol Oncol,2015,36(3):318-322.
[15]程静,潘光鑫,周素,等.宫颈癌发病机制的探讨.中国妇幼保健,2014,29(28)：4545-4547.
[16]姚春慧,李波,谭娟,等.子宫颈癌患者肿瘤标志物联合MRI影像诊断的临床价值.中国CT和MRI杂志,2017,15(6):103-106.
[17]王楠,马蓉,吴建中,等.宫颈癌的发病机制、诊断及治疗进展.中国肿瘤外科杂志,2013,5(2):121-124.
[18]杨辉,郑君.联合检测血清SCCA、CA19-9及CA125对宫颈癌诊断及预后判断的临床意义.中国妇幼保健,2013,28(5):772-774.
[19]颜萍,龚旭华.多种血清肿瘤标志物检测在早期宫颈癌诊断中的意义.实用癌症杂志,2014,29(7):741-743.
[20]左拥军,史丽静,谢雁.MRI扫描技术对诊断宫颈癌的临床研究.中国临床医生杂志,2017,45(2):83-86.
[21]张志娟,薛燕.TCT与高危型HPVDNA检测在宫颈癌筛查中的应用价值探讨.中国妇幼保健,2016,31(24):5339-5341.
[22]Cao W, Peng T, Zhou Y.Long noncoding RNA activated by transforming growth factorβ promotes cancer development and is a prognostic marker in cervical cancer.J Cancer Res Ther,2017,13(5):801.
[23]Li H, Sun G, Liu C,et al. PBX3 is associated with proliferation and poor prognosis in patients with cervical cancer. Onco Targets Ther,2017,10：5685-5694.
[24]Zhou LL, Shen Y, Gong JM, et al.MicroRNA466 with tumor markers for cervical cancer screening.Oncotarget,2017,8(41):70821-70827.

备注/Memo

备注/Memo:
*通讯作者，E-mail:bysyghy@163.com
更新日期/Last Update: 2018-05-10